NRx Pharmaceuticals, Inc.
http://www.neurorxpharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From NRx Pharmaceuticals, Inc.
Despite Trial Failure, NRx Leads In Bipolar
ANALYSIS: Few companies are pursuing therapies for bipolar disorder, but the few ongoing trials will yield data very shortly.
As 2024 Begins, US FDA’s Novel Agent Prospects Look A Lot Like 2023
Immuno-oncology will remain a major force at both FDA’s drugs and biologics centers, but watch for psychiatry and antibiotics to make some noise; rare pediatric diseases will remain prominent as the priority review voucher program heads into the sunset.
Deal Watch: Gurnet Point, Novo Holdings Buy Out Paratek
Struggling antibiotic company will go privare under the agreement. Bayer will employ Acuitas's liquid nanoparticle technology in gene therapies developed by subsidiary Asklepios.
Podcast: Psychiatric Disorders Markets: Depression, Bipolar Disorder And Schizophrenia
PODCAST: Datamonitor Healthcare analysts explore the three key psychiatric disorder markets from current market leaders to promising pipeline candidates and novel mechanisms.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- NeuroRx, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice